Claims:

1. Use of a peanut extract comprising denatured proteins for the manufacture of a medicament for reducing allergenicity of peanuts in an allergic subject, wherein said denatured proteins are derived from peanuts at a R5 developmental stage, wherein said proteins are denatured by cooking or heating to a temperature between 50-500 ºC, wherein said extract is essentially devoid of fully mature peanuts.

2. The use of claim 1, wherein said peanut extract is formulated for oral administration.

3. The use of claim 1, wherein said extract is provided in an amount between 0.1 - 2 gr of protein per week.

4. Use of a peanut extract comprising denatured proteins for the manufacture of a medicament for preventing allergenicity of peanuts in a subject, wherein said denatured proteins are derived from peanuts at a R5 developmental stage, wherein said proteins are denatured by cooking or heating to a temperature between 50-500 ºC, wherein said extract is essentially devoid of fully mature peanuts.

5. The use of claim 4, wherein said subject is an infant.